Results 1 to 10 of about 1,109,647 (111)
Application of C5 inhibitors in glomerular diseases in 2021 [PDF]
Kidney Research and Clinical Practice, 2022 The complement pathway is an essential mechanism in innate immunity, but it is also involved in multiple pathologies. For kidney diseases, strong evidence of a dysregulation in the alternative pathway in atypical hemolytic uremic syndrome (aHUS) led to ...
Alexis Werion, Eric Rondeau
doaj +3 more sources
Neurotrauma Reports, 2023 A potent effector of innate immunity, the complement system contributes significantly to the pathophysiology of traumatic brain injury (TBI). This study investigated the role of the complement cascade in neurobehavioral outcomes and neuropathology after ...
Min Chen +5 more
doaj +1 more source
Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices
Frontiers in Immunology, 2021 Complement activation is key to anti-microbial defenses by directly acting on microbes and indirectly by triggering cellular immune responses. Complement activation may also contribute to the pathogenesis of numerous inflammatory and immunological ...
Sinan Muldur +8 more
doaj +1 more source
Cells, 2023 Terminal complement complex (TCC) deposition was identified in human degenerated discs. To clarify the role of terminal complement activation in disc degeneration (DD), we investigated respective activating mechanisms and cellular effects in annulus ...
Amelie Kuhn +6 more
doaj +1 more source
A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention. [PDF]
PLoS ONE, 2018 The complement system is an intricate defense network that rapidly removes invading pathogens. Although many complement regulators are present to protect host cells under homeostasis, the impairment of Factor H (FH) regulatory mechanism has been ...
Nehemiah Zewde, Dimitrios Morikis
doaj +1 more source
BMC Nephrology, 2023 Background Thrombotic microangiopathy (TMA) is a potentially organ and life-threatening condition affecting patients with multiple myeloma (MM). Cases of proteasome inhibitor-induced TMA and specifically carfilzomib-induced TMA have been rarely reported ...
Lorenzo Catanese +2 more
doaj +1 more source
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Therapeutic Advances in Hematology, 2022 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by complement-mediated hemolysis, thrombosis, and various degrees of bone marrow dysfunction.
Raymond S.M. Wong
doaj +1 more source
Thrombosis and paroxysmal nocturnal haemoglobinuria
Thrombosis Update, 2021 Thrombosis is the most common, most feared complication of paroxysmal nocturnal haemoglobinuria (PNH), a striking example of the effect of uncontrolled complement activation and haemolysis on vascular biology and haemostasis.
Jean-Christophe Gris +6 more
doaj +1 more source
Haematologica, 2020 Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab.
Robert A. Brodsky +17 more
doaj +1 more source
Hematology, Transfusion and Cell Therapy, 2022 Clinical signs arising from intravascular hemolysis, hemolysis-related transfusions and thrombosis are indications for treatment initiation in paroxysmal nocturnal hemoglobinuria (PNH), whereas clone size per se is not.
Semra AYDIN
doaj +1 more source